Research programme: ORL1 antagonists - Adolor

Drug Profile

Research programme: ORL1 antagonists - Adolor

Alternative Names: ORL1 antagonists research programme - Adolor

Latest Information Update: 07 Oct 2003

Price : $50

At a glance

  • Originator Adolor Corporation
  • Class Small molecules
  • Mechanism of Action Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Neuropathic pain; Pain

Most Recent Events

  • 31 Dec 2002 Discontinued - Preclinical for Pain in USA (unspecified route)
  • 31 Dec 2002 Discontinued - Preclinical for Neuropathic pain in USA (unspecified route)
  • 26 Apr 2002 Preclinical trials in Pain in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top